The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
The company’s Growth Portfolio delivered $6.2 billion in revenue
Lifts full-year outlook as obesity drug boom accelerates
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
